Short course durvalumab remodels the tumour immune microenvironment in early stage triple negative breast cancer

Intismeran plus pembrolizumab improves recurrence free survival in resected high risk melanoma

ESMO 2026: Advances in NMIBC and MIBC

AI-based digital MammaPrint assay predicts recurrence risk and survival in early-stage breast cancer

UV1 vaccine combination shows no significant PFS improvement in BRCA wild type recurrent ovarian cancer

HBI-8000 plus nivolumab significantly improves progression-free survival in advanced melanoma

Camupepimut shows early disease free survival signal in resected KRAS mutated pancreatic cancer

TALENT: Neoadjuvant T-DXd with or without anastrozole, or in sequence with chemo for HER2-low, HR+ early-stage breast cancer

AI tool identifies patients most likely to benefit from extended endocrine therapy in hormone receptor-positive breast cancer

Extended letrozole improves disease-free survival in hormone receptor-positive breast cancer: 15-year results

Perioperative pembrolizumab fails to significantly improve event-free survival in muscle-invasive bladder cancer

Sacituzumab govitecan combination shows promising activity in first line metastatic urothelial cancer